Objective-The physiological function of the ATP-binding cassette G1 (ABCG1) transporter in humans is not yet elucidated, as no genetic disease caused by ABCG1 mutations has been documented. The goal of our study was, therefore, to investigate the potential role(s) of ABCG1 in lipid metabolism in humans. Methods and Results-Here we report that among the 104 polymorphisms present in the ABCG1 gene, the analysis of the frequent functional rs1893590 and rs1378577 single nucleotide polymorphisms located in the regulatory region of ABCG1 in the Regression Growth Evaluation Statin Study population revealed that both ABCG1 single nucleotide polymorphisms were significantly associated with plasma lipoprotein lipase (LPL) activity. Moreover, we observed that plasma LPL activity was modestly reduced in Abcg1 −/− mice as compared with control mice. Adipose tissue and skeletal muscle are the major tissues accounting for levels and activity of plasma LPL in the body. However, beyond its lipolytic action in the plasma compartment, LPL was also described to act locally at the cellular level. Thus, macrophage LPL was reported to promote foam cell formation and atherosclerosis in vivo. Analysis of the relationship between ABCG1 and LPL in macrophages revealed that the knockdown of ABCG1 expression (ABCG1 knockdown) in primary cultures of human monocyte-derived macrophages using small interfering RNAs led to a marked reduction of both the secretion and activity of LPL. Indeed, LPL was trapped at the cell surface of ABCG1 knockdown human monocytederived macrophages, likely in cholesterol-rich domains, thereby reducing the bioavailability and activity of LPL. As a consequence, LPL-mediated lipid accumulation in human macrophage foam cells in the presence of triglyceride-rich lipoproteins was abolished when ABCG1 expression was repressed. Conclusion-We presently report that ABCG1 controls LPL activity and promotes lipid accumulation in human macrophages in the presence of triglyceride-rich lipoproteins, thereby suggesting a potential deleterious role of macrophage ABCG1 in metabolic situations associated with high levels of circulating triglyceride-rich lipoproteins together with the presence of macrophages in the arterial wall. (Arterioscler Thromb Vasc Biol. 2012;32:2223-2231.)
T he ATP-binding cassette G1 (ABCG1) membrane transporter plays a key role in cellular lipid homeostasis in mice by mediating cellular free cholesterol efflux to high-density lipoprotein (HDL), 1 a major step in the reverse cholesterol transport pathway. Neutral lipid accumulation was observed in the lungs of Abcg1 −/− mice when fed a normal chow diet. 2 In addition, Abcg1 −/− mice failed to maintain cellular lipid homeostasis in both hepatocytes and in tissue macrophages after administration of a high-fat/high-cholesterol diet.
Atherosclerotic lesions are characterized by the presence of abundant lipid-laden, macrophage-derived foam cells, which result from the cellular uptake of modified lowdensity lipoprotein and triglyceride-rich lipoproteins (TRL) (mainly very low-density lipoprotein [VLDL] remnants) after infiltration into the arterial wall. 3 In this context, it is relevant that ABCG1 was initially proposed to potentially protect against macrophage foam cell formation during atherogenesis. We and others have indeed observed that net cholesterol efflux was reduced from Abcg1 −/− bone marrow-derived macrophages (BMDM) as compared with Abcg1 +/+ BMDM. 2, 4, 5 However, the specific role of macrophage ABCG1 in atherosclerosis in mice remains controversial as the invalidation of macrophage ABCG1 led to opposing effects on atherosclerosis progression when bone marrow from Abcg1 −/− mice was transplanted into irradiated Ldl-r −/− or ApoE −/− recipient mice. [6] [7] [8] Furthermore, we have recently demonstrated that, in contrast to mice, ABCG1 does not contribute significantly to cholesterol efflux in human macrophage foam cells. 9 In agreement with our findings, Chinetti-Gbaguidi et al 10 reported that the capacity of atheroprotective M2 macrophages isolated from human atherosclerotic lesions to promote cellular free cholesterol efflux was independent of ABCG1 expression, suggesting that ABCG1 could exert a more complex role in human macrophages.
To date, the physiological function of ABCG1 in lipid metabolism in humans remains indeterminate. Indeed, no genetic diseases caused by ABCG1 mutations have been described in humans, and no association between ABCG1 single nucleotide polymorphisms (SNPs) and human pathologies has been identified by Genome-Wide Association Studies (GWAS) (www.genome.gov/gwastudies). 11 Among the 104 SNPs described in the ABCG1 gene, 3 were identified in the 5′ regulatory region, 12 a region which may modulate ABCG1 gene expression. Only the 2 more proximal rs1378577 and rs1893590 SNPs, located at positions −134 (T/G) and −204 (A/C) from the transcription start site (NM_207627.1), respectively, have been reported as functional in either a population of 109 Japanese men with coronary artery disease 13 or in the 1473 Spanish subjects in the Hortega study. 14 To elucidate the potential role(s) of ABCG1 in lipid metabolism in humans, our strategy was, therefore, to determine the genotype of these 2 ABCG1 promoter variants (rs1893590 and rs1378577) in the dyslipidemic population of the lipid-lowering Regression Growth Evaluation Statin Study (REGRESS). 15 We observed that both SNPs located in the ABCG1 gene promoter were significantly associated with plasma lipoprotein lipase (LPL) activity. Consistent with this observation, ABCG1 expression was positively associated with LPL activity in human monocyte-derived macrophages. Moreover, our data indicate that ABCG1 regulates the bioavailability of macrophage-secreted LPL, thereby promoting lipid accumulation, primarily in the form of triglycerides, in primary human macrophages, with the potential for foam cell formation. These studies therefore identify ABCG1 as a major component in the uptake of TRL in human macrophages in controlling LPL bioavailability.
Methods
Expanded methods are available in the online-only Data Supplement.
Study Populations
The design of the REGRESS trial has been previously described. 15 The REGRESS study population is composed of 886 white men <70 years old, with a minimum 50% obstruction of a major coronary artery, plasma total cholesterol (TC) levels between 4 and 8 mmol/L (1.55 and 3.10 g/L), and plasma triglyceride concentrations of <4 mmol/L (3.5 g/L).
Results

Functional ABCG1 SNPs Are Associated With Plasma Lipoprotein Lipase Activity in REGRESS
The 2 ABCG1 SNPs occurred frequently in the REGRESS population: rs1378577 (T/G: 0.80/0.20) and rs1893590 (A/C: 0.74/0.26). Analysis of the potential association of rs1893590 and rs1378577 variants with plasma lipid levels and angiographic parameters revealed that neither of the 2 ABCG1 SNPs were associated with body mass index, plasma cholesteryl ester transfer protein concentration, plasma lipid levels (TC, low-density lipoprotein cholesterol, HDL-cholesterol, triglycerides and lipoprotein[a]), nor with angiographic parameters (minimum segment diameter and mean obstruction diameter) (Table) .
Interestingly, the 2 ABCG1 SNPs were strongly associated with LPL activity; individual homozygous for the less frequent allele of each polymorphism displayed the highest LPL activity. However, such an effect was not observed when plasma LPL mass was studied. The effect of each SNP on LPL activity was significant when no genetic model was assumed and this later remained significant when adjusted for age, smoking, and medication use as covariates. However, a recessive model appeared to be best fitting the data and was, therefore, assumed for analysis (Table) . Pairwise linkage disequilibrium analysis indicated that the rs1378577 and rs1893590 ABCG1 polymorphisms were in linkage disequilibrium in REGRESS (D′=0.96 and r 2 =0.68). A multilocus analysis indicated that those 2 ABCG1 SNPs were not independent predictors of plasma LPL activity, thereby suggesting that only a single SNP is functional and that the effect of the other is because of linkage disequilibrium. Additional experiments indicated that both ABCG1 SNPs were not associated with plasma regulators of LPL activity such as apolipoprotein C-II or apolipoprotein C-III (online-only Data Supplement). Analysis of the effect of the 2 polymorphisms, located in the promoter region of the ABCG1 gene, on promoter transcriptional activity indicated that both rs1378577 and rs1893590 SNPs significantly affected the ABCG1 promoter activity in gene reporter studies ( Figure 
Plasma Lipoprotein Lipase Activity is Subnormal in Abcg1 −/− Mice
To investigate the possible relationship between ABCG1 and LPL activity, we next measured plasma LPL activity in ABCG1-deficient mice (Abcg1 −/− ) before and after heparin injection ( Figure 1 ). When fed a chow diet, plasma LPL activity was significantly lower (−12%; P<0.01) in Abcg1 −/− mice as compared with Abcg1 +/+ mice after heparin injection, whereas LPL activity in preheparin plasma from Abcg1 +/+ and Abcg1 −/− mice was indistinguishable ( Figure 1A ). Analysis of plasma LPL protein by Western blots did not allow us to detect any differences in the amounts of LPL protein in postheparin plasmas between Abcg1 +/+ and Abcg1 −/− mice, whereas LPL protein was undetectable in preheparin plasmas ( Figure 1B-1C) .
These findings indicate that cellular ABCG1 expression is associated with plasma LPL activity in mice, with an attenuated LPL activity in the absence of ABCG1.
Silencing of ABCG1 in Human Macrophages Leads to Reduction in LPL Activity as a Consequence of LPL Retention at the Cell Surface
Adipose tissue and skeletal muscle are the major tissues accounting for level and activity of plasma LPL in the body. However, beyond its lipolytic action in the plasma compartment, LPL was also described to act locally at the cellular level, as described in the monocyte-derived macrophage, a key cell in the development of atherosclerosis. Indeed, macrophages and macrophage-derived foam cells constitute the primary source of LPL within the atherosclerotic lesion 16 and the expression of LPL in macrophages has been demonstrated to play a significant role in atherogenesis in mice. 17, 18 As shown in Figure 2A , human monocyte-derived macrophages (HMDM) differentiated for 12 days in the presence of human macrophage colony-stimulating factor displayed ≈100-fold higher amounts of LPL mRNA than freshly isolated human monocytes. To explore the potential relationship between ABCG1 expression and LPL activity in human macrophages, we silenced ABCG1 expression in HMDM using small interfering RNA specific for the human ABCG1 gene which led to an almost complete abolition of ABCG1 expression ( Figure 2B ). As shown in Figure 2C , LPL activity from ABCG1 knockdown (KD) HMDM was significantly reduced (−52%; P=0.02) as compared with control HMDM after heparin treatment, clearly indicating that ABCG1 impacts LPL activity from human macrophages to a major degree. Moreover, quantification of secreted LPL mass indicated that the amount of LPL protein released in the culture media from ABCG1 KD HMDM was significantly lower (−20%, P<0.05) than that from control cells ( Figure 2D ).
To determine whether the reduction in both the LPL secretion and activity observed in ABCG1 KD HMDM results from decrease in LPL expression, we next quantified LPL mRNA levels by real-time quantitative polymerase chain reaction in ABCG1-deficient macrophages. Interestingly, the KD of ABCG1 expression in human macrophages ( Figure 2E ) was not accompanied by reduction in LPL mRNA levels. Rather a minor increment in LPL mRNA levels (+28%; P<0.05) was detected in ABCG1 KD HMDM as compared with control HMDM ( Figure 2E ). Such an effect was also observed in Abcg1 -/-BMDM ( Figure 2F ; +25%; P<0.05). These data suggest that ABCG1 does not control LPL activity through modulation of LPL mRNA expression in human macrophages.
Table. Plasma and Angiographic Parameters as a Function of the rs1893590 and -rs1378577 ABCG1 Single Nucleotide Polymorphisms in Regression Growth Evaluation Statin Study
Although attenuated LPL activity in ABCG1 KD human macrophages did not result from reduction in cellular LPL mRNA expression, we next examined the possibility that secretion of LPL was impaired in macrophages when ABCG1 expression was deficient. Visualization of LPL in HMDM by confocal microscopy revealed that LPL expression at the cell surface of ABCG1 KD HMDM was much more pronounced than in control cells ( Figure 3A ). Treatment with heparin markedly reduced the immunorecognition of LPL at the cell surface; however, the abundance of LPL detected at the cell surface of ABCG1 KD HMDM still remained higher than that in control HMDM.
Consistent with our observations in HMDM, quantification of LPL at the cell surface of human THP-1 macrophages by fluorescence-activated cell sorting analysis ( Figure 3B ) revealed that the expression of LPL protein was markedly increased at the cell surface of ABCG1 KD THP-1 macrophages as compared with control cells in both the absence (+39%; P<0.005) and the presence (+28%; P<0.005) of heparin. Clearly then, invalidation of ABCG1 expression in human macrophages leads to cell surface retention of LPL at heparinresistant sites.
Altered Distribution of Cholesterol in ABCG1 KD Human Macrophages is Associated With the Retention of a Cellular LPL Fraction That Is Releasable Upon Cholesterol Depletion
A previous study reported that the heparin-resistant LPL fraction was dependent on the presence of cholesterol-enriched membrane structures, such as lipid rafts. 19, 20 To explore whether the retention of LPL at the cell surface of ABCG1 KD human macrophages was because of an increased formation of lipid rafts, we next analyzed the presence of such membrane structures by confocal microscopy by incubating cells with fluorescent cholera toxin, which binds to the pentasaccharide chain of plasma membrane ganglioside G M1 into lipid rafts. As observed in Figure 4A , the silencing of ABCG1 expression in HMDM was accompanied by an increased formation of lipid rafts as compared with control cells, indicating that membranes from ABCG1 KD human macrophages were enriched in cholesterol. Treatment with methyl-β-cyclodextrin, which A B removes cellular cholesterol and depletes cholesterol from lipid rafts, was proposed to favor the release of LPL from heparin-resistant sites. 19, 20 Incubation of HMDM with 1 mmol/L methyl-β-cyclodextrin at 37°C led to a reduction of cellular cholesterol mass (4 hours, −33%, 8 hours, −23%; P<0.005) and was associated with a time-dependent augmentation of secreted LPL protein in the culture media (+23% and +28% after 4 hours and 8 hours treatment, respectively, P<0.05) ( Figure 4B ). The fraction of LPL associated with cholesterol-enriched membrane domains released upon cholesterol depletion was then quantified from both control and ABCG1 KD HMDM ( Figure 4C ). We observed that the fraction of released LPL in the culture media upon treatment with 1 mmol/L methyl-β-cyclodextrin was ≈3-fold (P<0.05) more elevated in ABCG1 KD HMDM than in control cells, indicating that the localization of LPL in cholesterol-enriched membrane domains, such as lipid rafts, was increased when expression of ABCG1 was repressed.
Taken together, those findings indicate that ABCG1 deficiency in human macrophages favors the formation of cholesterol-rich membrane domains and increases the amount of LPL localized in heparin-resistant sites.
LPL-Mediated Lipid Accumulation in Human Macrophages Requires ABCG1
It is established that LPL is a key factor in promoting macrophage foam cell formation, mainly through its role in facilitating cellular lipoprotein uptake. 17, 21 To evaluate the potential pathophysiological relevance of the interaction between ABCG1 and LPL activity in foam cell formation, the capacity of VLDL to mediate cellular lipid accumulation was evaluated in control and ABCG1 KD HMDM ( Figure 5 ). Incubation of primary human macrophages with human VLDL for 24 hours led to marked elevation in cellular triglyceride ( Figure 5A ) and TC ( Figure 5B ) contents in control HMDM (+258% and +46% respectively, P<0.001). Specific inhibition of LPL activity by 10 µmol/L tetrahydrolipstatin (THL) reduced both triglyceride (TG) and TC accumulation induced by VLDL (−43% and −75%, respectively), thus illustrating the major role of LPL in cellular lipid accumulation. More strikingly, the VLDL-induced accumulation of TG in ABCG1 KD HMDM was markedly reduced (−38%; P<0.01) as compared with control cells, whereas that of cholesterol was completely abolished; such an effect was not observed when LPL activity was inhibited by tetrahydrolipstatin. Moreover, the capacity of tetrahydrolipstatin to inhibit LPL-mediated lipid uptake was abolished in ABCG1 KD macrophages, thus strengthening the specific concerted interaction between ABCG1 and LPL in VLDL uptake. Coherent with those observations, cellular lipid staining by Oil Red O confirmed that lipid accumulation upon VLDL incubation was reduced when ABCG1 expression was knocked down in HMDM ( Figure 5C ). Similar conclusions were reached in mouse macrophages (online-only Data Supplement). However, such cooperation between ABCG1 and LPL in the uptake of native or modified LDL (acetylated LDL and oxidized LDL) was not observed in human macrophages ( Figure III in the onlineonly Data Supplement), indicating that ABCG1 promotes macrophage lipid accumulation only in the presence of VLDL. Additional analysis indicated that mRNA levels of potential partners for LPL in VLDL uptake were not altered in ABCG1 KD macrophages (online-only Data Supplement).
Taken together, these data clearly indicate that ABCG1 plays a critical role in LPL-dependent lipid accumulation in human macrophages in the presence of TRL.
Discussion
Our present study identified a major role of ABCG1 in lipid accumulation in human macrophages via regulation of the bioavailability and the subsequent activity of LPL. As a result, ABCG1 contributes to macrophage foam cell formation in a context of TRL, a hallmark of atherosclerosis which is frequently observed in cardiometabolic diseases associated with hyperlipidemia.
In this study, we first demonstrated that ABCG1 polymorphisms were significantly associated with plasma LPL activity in the dyslipidemic population of the REGRESS study, whereas no association was found with the plasma lipid parameters studied. Such a lack of association between ABCG1 SNPs and plasma TC, low-density lipoprotein cholesterol or HDL-cholesterol was in agreement with the analysis of the rs1378577 ABCG1 SNP in a small Japanese population of 109 male patients with coronary artery disease 13 and with a recent study analyzing 2 other ABCG1 SNPs in a large cohort of 1021 Chinese coronary artery disease patients. 22 Consistent with our findings, the absence of Abcg1 in mice was not accompanied by alteration of plasma lipid levels in Abcg1 −/− mice as compared with control animals. 2 Taken together with our data, it appears that ABCG1 indeed does not play a significant role in regulating plasma lipid metabolism in humans. Although both rs1893590 and rs1378577 SNPs were associated with LPL activity, we were not able to detect any association between both markers and plasma TG levels in the REGRESS study population. Consistent with this result, we presently report that although LPL activity was reduced in Abcg1 −/− mice (Figure 1) , those mice were not described to be hypertriglyceridemic when fed a high-cholesterol/high-fat diet. Taken together, those observations suggest that although the regulation of LPL by ABCG1 likely does not occur only in macrophages in vivo, the latter was, in all likelihood, not effective in parenchymal cells and, therefore, strongly indicate that ABCG1 is not involved in a regulatory step in LPLmediated TG lipolysis. However, the regulation of LPL activity by ABCG1 in macrophages likely does not account for the effect observed in vivo on postheparin plasma LPL activity, leading us to suggest that ABCG1 might control LPL activity in a tissue that contributes largely to plasma LPL levels, such as adipose tissue or skeletal muscle. Indeed, the macrophagespecific expression of human LPL in transgenic rabbits 23 or in transgenic mice 24 was not accompanied by an increase of postheparin plasma LPL activity in those animals. In addition, transplantation of Lpl −/− bone marrow 18, 25 or Lpl −/− fetal liver cells 17 into irradiated mice had no impact on postheparin plasma LPL activity as compared with animals transplanted with Lpl +/+ cells. Consistent with this point of view, we observed that silencing of ABCG1 expression in mature mouse adipocytes led to a marked reduction of LPL activity similar to that observed in macrophages (data not shown).
Our findings revealed that the presence of ABCG1 is required for the optimal bioavailability and activity of LPL produced by human macrophages. Thus, we observed that the silencing of ABCG1 expression in human macrophages was accompanied by the entrapment of the LPL protein at the cell surface mostly at heparin-resistant sites (Figure 3 ), in cholesterol-enriched membrane domains accessible to mβCD (Figure 4 ). Such retention of LPL at the cell surface in cholesterol-enriched membrane domains, therefore, reduces the bioavailability of LPL and thus inhibits its biological activities. Our study supports the role of ABCG1 in the intracellular trafficking of cholesterol in macrophages very recently described by Tarling et al. 26 Indeed, there is now a growing body of evidence indicating that ABCG1 localizes in the intracellular regulated secretory pathway rather than at the plasma membrane. 26, 27 In macrophages, ABCG1 was mainly identified in endosomes and was proposed to redistribute intracellular cholesterol away from the endoplasmic reticulum by transporting it to plasma membrane through the endosome pathway. Consistent with such an intracellular role of ABCG1, loss of ABCG1 led to reduced cholesterol levels in granules and an impaired insulin secretion from pancreatic β cells in Abcg1 −/− mice. 27 Interestingly, this reduced cholesterol content in granules from ABCG1-deficient cells was accompanied by a significant increase of the cholesterol content in plasma membrane in domains accessible to mβCD. 27 In total agreement with this latter study, we, therefore, propose a similar mechanism by which the efficient transport of cholesterol through the endosome pathway operated by ABCG1 ensures the effective secretion of LPL from human macrophages and its binding to proteoglycans. By contrast, alteration of the endosomal cholesterol transport in ABCG1-deficient cells leads to an accumulation of cholesterol at the plasma membrane ( Figure  4A ) and to the subsequent retention of LPL at the cell surface ( Figure 3A ) in cholesterol-rich domains accessible to mβCD. Coherent with this mechanism, the plasma membrane cholesterol content, as well as the cell-surface expression of either toll-like receptor 4 or interleukin-3/GM-CSF receptor were increased in Abcg1 −/− macrophages 28 and Abcg1 −/− myeloid cells, 29 respectively. It is noteworthy that this increase of the cholesterol content in plasma membrane likely occurs in sites that are distinct to those required for cellular cholesterol efflux in human macrophages since ABCG1 deficiency has no significant effect on free cholesterol efflux to extracellular acceptors. 9 In accordance with the latter observation, cholesterol efflux to HDL and apolipoprotein A-I was not altered from Abcg1-deficent mouse β cells despite an accumulation of cholesterol at the plasma membrane level in those cells. 27 In our present study, it is, however, noteworthy that the large amount of LPL trapped at the cell surface of ABCG1 KD human macrophages was associated with a marked decrease of postheparin LPL activity, but a modest matching reduction of postheparin LPL mass in the culture media ( Figure 2 ). This observation led us to suggest that ABCG1 likely controls the bioavailability of catalytically active LPL rather than that of the total pool of cellular LPL. Thus, the silencing of ABCG1 expression in human macrophages would preferentially retain the fraction of active LPL at the cell surface, rendering it biologically inactive, whereas most LPL produced by human macrophages turned out to be inactive. 19 This mechanism is consistent with our in vivo observation in the REGRESS population and in mice in which the effect of ABCG1 on postheparin LPL activity was independent of postheparin LPL mass.
The observation that ABCG1 modulates macrophage LPL activity is interesting because a large body of evidence clearly indicates that macrophage LPL promotes foam cell formation and atherosclerosis in vivo in the arterial wall. 18, 25 In the present study, we identified ABCG1 as being a prerequisite for LPL-mediated lipid accumulation in human macrophages in the presence of TRL. Indeed, the silencing of ABCG1 expression using small interfering RNA in primary cultures of human macrophages led to a marked reduction of secreted LPL activity and abolished the cellular TG and cholesterol accumulation dependent on LPL ( Figure 5 ). This effect likely resulted from the abrogation of the uptake of TRL particles mediated by LPL. Indeed, a mechanism involving the uptake of the whole TRL particle by LPL, which has now been documented, 21, 30 is supported by the observation that both triglycerides and cholesterol accumulation were altered in ABCG1 KD human macrophages when incubated with VLDL.
Such a role of ABCG1 in favoring foam cell formation, therefore, would suggest that ABCG1 could exert a proatherogenic action in the arterial wall. Indeed, although macrophage LPL activity was not totally abolished when ABCG1 expression was repressed (Figure 2 ), this effect could nevertheless appear sufficient to impact atherosclerosis development. Indeed, Babaev et al 17, 25 clearly reported a dose-dependent effect of macrophage LPL on aortic lesion area in irradiated mice transplanted with Lpl −/− , Lpl −/+ , and Lpl +/+ fetal liver cells.
However, the relationship between ABCG1 and either atherosclerosis in mouse models 31 or coronary artery disease in humans 22, 32 is not clear. In our study, the ABCG1 SNPs were not associated with angiographic parameters such as the minimum obstruction diameter or the mean segment diameter in the REGRESS study population. Taken together, our findings suggest that the accumulation of lipid, mainly triglycerides, operated by ABCG1 in macrophages might be considered as proatherogenic mainly in hypertriglyceridemic subjects, which represent only a subset of patients with atherosclerostic disease. Indeed, the large amounts of TRL observed in hypertriglyceridemia are highly atherogenic, as it is well established that TRL may penetrate the arterial wall and favor lipid accumulation and subsequent foam cell formation. 33 However, the absence of effect of the ABCG1 SNPs on atherosclerosis progression may also reflect a not yet identified role of human ABCG1 in the vascular wall, which would be potentially antiatherogenic. Indeed, ABCG1 was proposed to protect against endothelial dysfunction in mice, by promoting the efflux of oxysterols from endothelial cells to HDL and then favoring the NO release 34, 35 and we cannot exclude that such a role for ABCG1 may counterbalance its potentially proatherogenic action in macrophages.
The present study, therefore, constitutes the first evidence for a major role for ABCG1 in human pathophysiology. Indeed, we report that ABCG1 promotes cellular lipid accumulation in human macrophages and thus contributes to human macrophage foam cell formation, potentially with pathophysiological consequences in metabolic situations associated with chronic or transient hypertriglyceridemia.
